118 related articles for article (PubMed ID: 7499442)
1. In vitro investigation of a combination of two drugs, cisplatin and carboplatin, as a function of the area under the c/t curve.
Kobayashi K; Kudoh S; Takemoto T; Hino M; Hayashihara K; Nakahiro K; Ando M; Niitani H
J Cancer Res Clin Oncol; 1995; 121(12):715-20. PubMed ID: 7499442
[TBL] [Abstract][Full Text] [Related]
2. [Probability of the combination use of cisplatin and carboplatin].
Kobayashi K; Hino M; Hayashihara K; Niitani H
Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2684-92. PubMed ID: 2277219
[TBL] [Abstract][Full Text] [Related]
3. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
4. A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party.
Sculier JP; Paesmans M; Thiriaux J; Lecomte J; Bureau G; Giner V; Koumakis G; Lafitte JJ; Berchier MC; Alexopoulos CG; Zacharias C; Mommen P; Ninane V; Klastersky J
Eur J Cancer; 1999 Sep; 35(9):1314-9. PubMed ID: 10658520
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
6. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
Groen HJ; Sleijfer S; Meijer C; Kampinga HH; Konings AW; De Vries EG; Mulder NH
Br J Cancer; 1995 Dec; 72(6):1406-11. PubMed ID: 8519652
[TBL] [Abstract][Full Text] [Related]
8. The cytotoxic activity of cisplatin, carboplatin and teniposide alone and combined determined on four human small cell lung cancer cell lines by the clonogenic assay.
Roed H; Vindeløv LL; Christensen IJ; Spang-Thomsen M; Hansen HH
Eur J Cancer Clin Oncol; 1988 Feb; 24(2):247-53. PubMed ID: 2833402
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
Belani CP; Kearns CM; Zuhowski EG; Erkmen K; Hiponia D; Zacharski D; Engstrom C; Ramanathan RK; Capozzoli MJ; Aisner J; Egorin MJ
J Clin Oncol; 1999 Feb; 17(2):676-84. PubMed ID: 10080614
[TBL] [Abstract][Full Text] [Related]
10. Validation of the limited-sampling models for carboplatin AUC in combination chemotherapy with taxanes.
Miyazaki M; Oguri T; Kurata T; Takahashi T; Daga H; Fujitaka K; Isobe T; Nakajima M; Fujiwara Y; Kohno N
Anticancer Res; 2004; 24(3b):1911-4. PubMed ID: 15274375
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies.
Perez RP; Chen E; Thaddeus Beck J; Shirai K; Neil Hayes D; Shen T; Baldwin JR; Bryant KB; He S; Chin S
Pharmacol Res Perspect; 2019 Dec; 7(6):e00519. PubMed ID: 31788317
[TBL] [Abstract][Full Text] [Related]
12. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
13. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
Zhou Y; Pan DS; Shan S; Zhu JZ; Zhang K; Yue XP; Nie LP; Wan J; Lu XP; Zhang W; Ning ZQ
Biomed Pharmacother; 2014 May; 68(4):483-91. PubMed ID: 24721323
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-induced apoptosis of mesothelioma cells is affected by potassium ion flux modulator amphotericin B and bumetanide.
Marklund L; Henriksson R; Grankvist K
Int J Cancer; 2001 Aug; 93(4):577-83. PubMed ID: 11477563
[TBL] [Abstract][Full Text] [Related]
15. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
16. Modulation of sensitivity to cis-diamminedichloroplatinum (II) by thromboxane A2 receptor antagonists in non-small-cell lung cancer cell lines.
Kasahara K; Fujimura M; Bando T; Shibata K; Shirasaki H; Matsuda T
Br J Cancer; 1996 Nov; 74(10):1553-8. PubMed ID: 8932334
[TBL] [Abstract][Full Text] [Related]
17. Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: A clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer.
Daga H; Isobe T; Miyazaki M; Fujitaka K; Kondo K; Kohno N
Oncol Rep; 2004 Jun; 11(6):1225-31. PubMed ID: 15138560
[TBL] [Abstract][Full Text] [Related]
18. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Sasaki Y; Shinkai T; Eguchi K; Tamura T; Ohe Y; Ohmori T; Saijo N
Cancer Chemother Pharmacol; 1991; 27(4):263-70. PubMed ID: 1847845
[TBL] [Abstract][Full Text] [Related]
19. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
